KalVista rises after licensing deal with Kaken for lead asset in Japan
Source: SeekingAlpha
2025-04-08 07:09:28 ET
More on KalVista, Kaken, etc.
- Alumis rises on licensing deal with Japan’s Kaken
- KalVista Pharmaceuticals initiated with Market Outperform rating at JMP
- Seeking Alpha’s Quant Rating on KalVista Pharmaceticals
- Historical earnings data for KalVista Pharmaceticals
- Financial information for KalVista Pharmaceticals
Read the full article on Seeking Alpha
For further details see:
KalVista rises after licensing deal with Kaken for lead asset in Japan
Kaken Pharmaceutical Co Ltd
NASDAQ: KKPCF
KKPCF Trading
169.36% G/L:
$28.121 Last:
578 Volume:
$28.121 Open:
